이뮨온시아
Financials
Valuation Metrics
이뮨온시아's Market Cap is ₩3012B. Ranked #654 of 2,421 in KR market (top 27%), #272 of 1,640 on KOSDAQ (top 17%), #70 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 301.17B KRW | KR#654/2,421 Sec#70/231 |
| Revenue | 111.2M KRW | KR#2,393/2,421 Sec#224/231 |
| Net Income | -27.36B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 33.15B KRW | KR#2,316/2,421 Sec#217/231 |
| Net Assets | 28.42B KRW | KR#2,189/2,421 Sec#198/231 |
| Value | ||
| P/B | 10.60x | KR#2,363/2,421 Sec#212/231 |
| P/S | 2708.15x | KR#2,412/2,421 Sec#227/231 |
| FCF Yield | -7.67% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -96.30% | KR#2,340/2,421 Sec#216/231 |
| ROA | -82.55% | KR#2,390/2,421 Sec#225/231 |
| Op. Margin | -25182.04% | KR#2,393/2,421 Sec#224/231 |
| Financial Health | ||
| Debt Ratio | 16.65% | KR#289/2,421 Sec#43/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -23.10B KRW | KR#1,930/2,421 Sec#186/231 |
| Cash | 8.24B KRW | KR#1,800/2,421 Sec#159/231 |
| Current Ratio | 6.22x | KR#202/2,421 Sec#39/231 |
| Performance | ||
| 1Y Return | -41.85% | KR#1,878/2,421 Sec#159/231 |
| 1M Return | 10.94% | KR#455/2,421 Sec#30/231 |
| From 52W High | -78.74% | KR#2,331/2,421 Sec#214/231 |
| 1Y MDD | -83.48% | KR#2,345/2,421 Sec#223/231 |
| Trading | ||
| Volume | 1,243,270 shares | KR#113/2,421 Sec#8/231 |
| Trading Value | 4.12B KRW | KR#406/2,421 Sec#39/231 |
| Foreign Own. | 3.36% | KR#1,184/2,421 Sec#110/231 |
| Per Share | ||
| EPS | -299 KRW | KR—/2,421 Sec—/231 |
| BPS | 311 KRW | KR#2,408/2,421 Sec#230/231 |
Company Info
IMMUNEONCIA, established in 2016, is a specialized company developing antibody-based immune-oncology drugs, slated for KOSDAQ listing in 2025 as a technology growth company. It holds Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies as core assets, generating revenue through new drug candidate development and early clinical technology transfers. IMMUNEONCIA aims to be the first domestic leader in commercializing Anti-PD-L1 immune-oncology drugs and is concentrating on research and development to launch global blockbuster new drugs. Its headquarters are located in Yongin-si, Gyeonggi-do.